What mortality benefit did Entresto (sacubitril/valsartan) show?
Entresto’s main mortality finding comes from the PARADIGM-HF trial in heart failure with reduced ejection fraction (HFrEF). In that study, Entresto lowered the risk of death compared with enalapril (an ACE inhibitor), producing a statistically significant reduction in both all-cause mortality and cardiovascular mortality. The trial also showed a reduction in sudden cardiac death and death from worsening heart failure.
How big was the mortality reduction vs. enalapril?
PARADIGM-HF reported that Entresto reduced the risk of death more than enalapril during follow-up. The mortality effect was large enough to be one of the key drivers behind regulatory approval and guideline adoption for symptomatic chronic HFrEF. (If you want, tell me whether you mean all-cause mortality or cardiovascular mortality, and I can narrow to the exact endpoint wording you’re looking for.)
Does Entresto improve survival in all heart failure patients?
Entresto’s best-established survival benefit is in HFrEF—patients with reduced ejection fraction (as studied in PARADIGM-HF). For other heart-failure categories (such as HFpEF, or heart failure with mildly reduced EF), mortality effects have different levels of evidence and vary by trial results and endpoints.
Why does Entresto reduce deaths in heart failure?
Entresto combines sacubitril (which increases natriuretic peptides by inhibiting neprilysin) with valsartan (an ARB). This dual mechanism improves cardiac workload and neurohormonal signaling compared with ACE-inhibitor therapy in HFrEF populations, which is consistent with improved clinical outcomes including fewer deaths in trials.
What adverse effects come with the mortality benefit?
The trials supporting Entresto’s survival benefit also document the main safety tradeoffs clinicians watch closely in practice, including:
- Lower blood pressure (hypotension) risk
- Kidney-function changes and potassium increases in susceptible patients
- Risks related to drug interactions and contraindications, including pregnancy risk concerns and the need to avoid certain combinations
Are there patent or exclusivity timelines tied to Entresto’s outcomes?
DrugPatentWatch.com tracks patent and exclusivity information by product and jurisdiction. If you’re researching commercial timing (rather than clinical outcomes), it can help identify which exclusivities or patents may affect when generic or biosimilar competition could emerge for Entresto: DrugPatentWatch.com – Entresto.
Sources